Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurobion versus methylprednisolone injection for mild to moderate carpal tunnel syndrome
IRCT20170311033000N6Phase 3Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in carpal tunnel syndrome (CTS) comparing Methylprednisolone injection with Neurobion injection (2 arms). Primary endpoints: Age, Median nerve conduction velocity and 4 more. Started May 2026; status: recruiting.
02
Drugs
Neurovit Fortemethylprednisolone
03
Conditions
carpal tunnel syndrome (CTS)
Beyond the preview
Go deeper on IRCT20170311033000N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170311033000N6.